Advances in the diagnosis and management of pediatric Langerhans cell histiocytosis and Rosai-Dorfman disease: therapies, biomarkers, and response assessment

2.

Chakraborty

R

,

Burke

TM

,

Hampton

OA

, et al.

Alternative genetic mechanisms of BRAF activation in Langerhans cell histiocytosis

.

Blood

.

2016

;

128

(

21

):

2533

-

2537

.

3.

Berres

M-L

,

Lim

K-P

,

Peters

T

, et al.

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

.

J Exp Med

.

2014

;

211

(

4

):

669

-

683

.

4.

Gadner

H

,

Minkov

M

,

Grois

N

, et al;

Histiocyte Society

.

Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis

.

Blood

.

2013

;

121

(

25

):

5006

-

5014

.

5.

Lin

H

,

Batajoo

A

,

Peckham-Gregory

E

, et al.

BRAF V600E-positive mononuclear cells in blood at diagnosis portend treatment failure and neurodegeneration in pediatric LCH

.

Blood

.

2025

;

146

(

2

):

206

-

218

.

6.

Ballester

LY

,

Cantu

MD

,

Lim

KPH

, et al.

The use of BRAF V600E mutation-specific immunohistochemistry in pediatric Langerhans cell histiocytosis

.

Hematol Oncol

.

2018

;

36

(

1

):

307

-

315

.

7.

Phan

DAT

,

Phung

GB

,

Duong

TT

, et al.

The Value of BRAF VE1 immunoexpression in pediatric Langerhans cell histiocytosis

.

Fetal Pediatr Pathol

.

2022

;

41

(

4

):

558

-

567

.

8.

Picarsic

J

,

Jaffe

R

.

Pathology of histiocytic disorders and neoplasms and related disorders

. In:

Janka

G

,

Abla

G

, eds.

Histiocytic Disorders

.

Springer International

;

2017

:

3

-

50

.

9.

Abla

O

,

Jacobsen

E

,

Picarsic

J

, et al.

Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease

.

Blood

.

2018

;

131

(

26

):

2877

-

2890

.

10.

Garces

S

,

Medeiros

LJ

,

Patel

KP

, et al.

Mutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai-Dorfman disease

.

Mod Pathol

.

2017

;

30

(

10

):

1367

-

1377

.

11.

Binhassan

S

,

Samman

M

,

Al-Sheikh

Y

, et al.

Revisiting the molecular landscape of Rosai-Dorfman disease: insights from whole exome sequencing of Saudi patients

.

Front Oncol

.

2025

;

15

:

1556830

.

12.

Goyal

G

,

Ravindran

A

,

Young

JR

, et al;

Mayo Clinic Histiocytosis Working Group

.

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease

.

Haematologica

.

2020

;

105

(

2

):

348

-

357

.

13.

McClain

KL

,

Picarsic

J

,

Chakraborty

R

, et al.

CNS Langerhans cell histiocytosis: common hematopoietic origin for LCH-associated neurodegeneration and mass lesions

.

Cancer

.

2018

;

124

(

12

):

2607

-

2620

.

14.

Weitzman

S

,

Egeler

RM.

Langerhans cell histiocytosis: update for the pediatrician

.

Curr Opin Pediatr

.

2008

;

20

(

1

):

23

-

29

.

15.

Gadner

H

,

Grois

N

,

Pötschger

U

, et al;

Histiocyte Society

.

Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification

.

Blood

.

2008

;

111

(

5

):

2556

-

2562

.

16.

Hélias-Rodzewicz

Z

,

Donadieu

J

,

Terrones

N

, et al;

French Histiocytosis Study Group

.

Molecular and clinicopathologic characterization of pediatric histiocytoses

.

Am J Hematol

.

2023

;

98

(

7

):

1058

-

1069

.

17.

Allen

CE

,

Merad

M

,

McClain

KL.

Langerhans-cell histiocytosis

.

N Engl J Med

.

2018

;

379

(

9

):

856

-

868

.

18.

Chakraborty

R

,

Hampton

OA

,

Shen

X

, et al.

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

.

Blood

.

2014

;

124

(

19

):

3007

-

3015

.

19.

Khoury

JD

,

Solary

E

,

Abla

O

, et al.

The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms

.

Leukemia

.

2022

;

36

(

7

):

1703

-

1719

.

20.

Lim

KPH

,

Milne

P

,

Poidinger

M

, et al.

Circulating CD1c+ myeloid dendritic cells are potential precursors to LCH lesion CD1a+CD207+ cells

.

Blood Adv

.

2020

;

4

(

1

):

87

-

99

.

21.

Milne

P

,

Abhyankar

H

,

Scull

B

, et al.

Cellular distribution of mutations and association with disease risk in Langerhans cell histiocytosis without BRAFV600E

.

Blood Adv

.

2022

;

6

(

16

):

4901

-

4904

.

22.

Diamond

EL

,

Durham

BH

,

Haroche

J

, et al.

Diverse and targetable kinase alterations drive histiocytic neoplasms

.

Cancer Discov

.

2016

;

6

(

2

):

154

-

165

.

23.

Brown

NA

,

Furtado

LV

,

Betz

BL

, et al.

High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis

.

Blood

.

2014

;

124

(

10

):

1655

-

1658

.

24.

Bigenwald

C

,

Le Berichel

J

,

Wilk

CM

, et al.

BRAFV600E-induced senescence drives Langerhans cell histiocytosis pathophysiology

.

Nat Med

.

2021

;

27

(

5

):

851

-

861

.

25.

Gao

X-M

,

Li

J

,

Cao

X-X

.

Signaling pathways, microenvironment, and targeted treatments in Langerhans cell histiocytosis

.

Cell Commun Signal

.

2022

;

20

(

1

):

195

.

26.

Petersen

BL

,

Rengtved

P

,

Bank

MI

,

Carstensen

H.

High expression of markers of apoptosis in Langerhans cell histiocytosis

.

Histopathology

.

2003

;

42

(

2

):

186

-

193

.

27.

Marchal

J

,

Kambouchner

M

,

Tazi

A

,

Valeyre

D

,

Soler

P.

Expression of apoptosis- regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis

.

Histopathology

.

2004

;

45

(

1

):

20

-

28

.

28.

Bank

MI

,

Gudbrand

C

,

Rengtved

P

, et al.

Immunohistochemical detection of the apoptosis-related proteins FADD, FLICE, and FLIP in Langerhans cell histiocytosis

.

J Pediatr Hematol Oncol

.

2005

;

27

(

6

):

301

-

306

.

29.

Wang

C-J

,

Zhu

T

,

Zhao

C-Z

, et al.

BRAF-V600E mutations in plasma and peripheral blood mononuclear cells correlate with prognosis of pediatric Langerhans cell histiocytosis treated with first-line therapy

.

Pediatr Blood Cancer

.

2024

;

71

(

9

):

e31099

.

30.

Kudo

K

,

Toki

T

,

Kanezaki

R

, et al.

BRAF V600E-positive cells as molecular markers of bone marrow disease in pediatric Langerhans cell histiocytosis

.

Haematologica

.

2022

;

107

(

7

):

1719

-

1725

.

31.

Parekh

D

,

Lin

H

,

Batajoo

A

, et al.

Clofarabine monotherapy in aggressive, relapsed and refractory Langerhans cell histiocytosis

.

Br J Haematol

.

2024

;

204

(

5

):

1888

-

1893

.

32.

Eckstein

OS

,

Visser

J

,

Rodriguez-Galindo

C

,

Allen

CE

;

NACHO-LIBRE Study Group

.

Clinical responses and persistent BRAF V600E+ blood cells in children with LCH treated with MAPK pathway inhibition

.

Blood

.

2019

;

133

(

15

):

1691

-

1694

.

33.

Galluzzo Mutti

L

,

Picarsic

J.

Updates on Langerhans cell histiocytosis and other histiocytosis in children: invited review-challenges and novelties in paediatric tumours

.

Virchows Arch

.

2025

;

486

(

1

):

189

-

204

.

34.

Galluzzo

Mutti ML

,

Picarsic

J.

Pediatric pathology: emerging entities, current trends, and comprehensive updates, ‘Histiocytosis’

.

Surg Pathol Clin

.

2025

;

18

(

2

):

341

-

358

.

35.

Pratap

T

,

Jalal

MJA

,

R

,

Gopalakrishnabhakthan

A

,

Ak

V.

Hepatobiliary and gastrointestinal involvement in Langerhans cell histiocytosis-spectrum of three cases

.

Indian J Radiol Imaging

.

2021

;

31

(

3

):

670

-

677

.

36.

Wang

L

,

Yang

F

,

Ding

Y

, et al.

Gastrointestinal Langerhans cell histiocytosis with unifocal, single-system involvement in adults: cases report and literature review

.

J Clin Lab Anal

.

2022

;

36

(

12

):

e24765

.

37.

Fu

Z

,

Li

H

,

Arslan

ME

,

Ells

PF

,

Lee

H.

Hepatic Langerhans cell histiocytosis: a review

.

World J Clin Oncol

.

2021

;

12

(

5

):

335

-

341

.

38.

McKinney

RA

,

Wang

G

.

Langerhans cell histiocytosis and other histiocytic lesions

.

Head Neck Pathol

.

2025

;

19

(

1

):

26

.

39.

Powell

P

,

Vitug

G

,

Castro-Silva

F

,

Ray

A.

A rare case of CD1a-negative Langerhans cell histiocytosis of the central nervous system in a child

.

Clin Case Rep

.

2017

;

5

(

10

):

1664

-

1667

.

40.

Grois

N

,

Pötschger

U

,

Prosch

H

, et al;

DALHX- and LCH I and II Study Committee

.

Risk factors for diabetes insipidus in Langerhans cell histiocytosis

.

Pediatr Blood Cancer

.

2006

;

46

(

2

):

228

-

233

.

41.

Simko

SJ

,

McClain

KL

,

Allen

CE.

Up-front therapy for LCH: is it time to test an alternative to vinblastine/prednisone?

Br J Haematol

.

2015

;

169

(

2

):

299

-

301

.

42.

Allen

CE

,

Ladisch

S

,

McClain

KL.

How I treat Langerhans cell histiocytosis

.

Blood

.

2015

;

126

(

1

):

26

-

35

.

43.

Chang

L

,

Lang

M

,

Lin

H

, et al.

Phase 2 study using low dose cytarabine for adult patients with newly diagnosed Langerhans cell histiocytosis

.

Leukemia

.

2024

;

38

(

4

):

803

-

809

.

44.

Eckstein

OS

,

Bernhardt

MB

,

Hood

CG

,

Karri

V

,

Kralik

SF

,

McClain

KL.

Treatment of Langerhans cell histiocytosis with subcutaneous cytarabine

.

Pediatr Hematol Oncol

.

2023

;

40

(

5

):

497

-

505

.

45.

Go

RS

,

Jacobsen

E

,

Baiocchi

R

, et al.

Histiocytic Neoplasms, Version 2.2021, NCCN clinical practice guidelines in oncology

.

J Natl Compr Canc Netw

.

2021

;

19

(

11

):

1277

-

1303

.

46.

Cournoyer

E

,

Ferrell

J

,

Sharp

S

, et al.

Dabrafenib and trametinib in Langerhans cell histiocytosis and other histiocytic disorders

.

Haematologica

.

2024

;

109

(

4

):

1137

-

1148

.

47.

Gaspari

S

,

Di Ruscio

V

,

Stocchi

F

,

Carta

R

,

Becilli

M

,

De Ioris

MA

.

Case report: early association of vemurafenib to standard chemotherapy in multisystem Langerhans cell histiocytosis in a newborn: taking a chance for a better outcome?

Front Oncol

.

2021

;

11

:

794498

.

48.

Abla

O.

Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease

.

Hematol Am Soc Hematol Educ Program

.

2023

;

2023

(

1

):

386

-

395

.

49.

Donadieu

J

,

Larabi

IA

,

Tardieu

M

, et al.

Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study

.

J Clin Oncol

.

2019

;

37

(

31

):

2857

-

2865

.

50.

Reiner

AS

,

Durham

BH

,

Yabe

M

, et al.

Outcomes after interruption of targeted therapy in patients with histiocytic neoplasms

.

Br J Haematol

.

2023

;

203

(

3

):

389

-

394

.

51.

Wojciechowska

N

,

Richards

AE

,

Anthony

A

, et al.

Targeted therapy in pediatric Langerhans cell histiocytosis: describing a novel strategy to minimize long-term exposure while maintaining efficacy

.

Pediatr Blood Cancer

.

2025

;

72

(

11

):

e32016

.

52.

Awada

G

,

Seremet

T

,

Fostier

K

,

Everaert

H

,

Neyns

B.

Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition

.

Blood Adv

.

2018

;

2

(

16

):

2156

-

2158

.

53.

Diamond

A.

From mutation to management: advancing Langerhans cell histiocytosis treatment through combination therapies

.

Br J Haematol

.

2024

;

204

(

5

):

1588

-

1589

.

54.

Ascierto

PA

,

McArthur

GA

,

Dréno

B

, et al.

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

.

Lancet Oncol

.

2016

;

17

(

9

):

1248

-

1260

.

55.

Poulikakos

PI

,

Zhang

C

,

Bollag

G

,

Shokat

KM

,

Rosen

N.

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

.

Nature

.

2010

;

464

(

7287

):

427

-

430

.

56.

Peng

S-B

,

Henry

J-R

,

Kaufman

M-D

, et al.

Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers

.

Cancer Cell

.

2015

;

28

(

3

):

384

-

398

.

57.

Hatzivassiliou

G

,

Song

K

,

Yen

I

, et al.

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

.

Nature

.

2010

;

464

(

7287

):

431

-

435

.

58.

Hyman

DM

,

Puzanov

I

,

Subbiah

V

, et al.

Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations

.

N Engl J Med

.

2015

;

373

(

8

):

726

-

736

.

59.

Cohen Aubart

F

,

Idbaih

A

,

Emile

J-F

, et al.

Histiocytosis and the nervous system: from diagnosis to targeted therapies

.

Neuro Oncol

.

2021

;

23

(

9

):

1433

-

1446

.

60.

Goyal

G

,

Tazi

A

,

Go

RS

, et al.

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults

.

Blood

.

2022

;

139

(

17

):

2601

-

2621

.

61.

Whitlock

JA

,

Geoerger

B

,

Dunkel

IJ

, et al.

Dabrafenib, alone or in combination with trametinib, in BRAF V600-mutated pediatric Langerhans cell histiocytosis

.

Blood Adv

.

2023

;

7

(

15

):

3806

-

3815

.

62.

Yang

Y

,

Wang

D

,

Cui

L

, et al.

Effectiveness and safety of dabrafenib in the treatment of 20 Chinese children with BRAFV600E-mutated Langerhans cell histiocytosis

.

Cancer Res Treat

.

2021

;

53

(

1

):

261

-

269

.

63.

Friedman

JS

,

Durham

BH

,

Reiner

AS

, et al.

Mixed histiocytic neoplasms: a multicentre series revealing diverse somatic mutations and responses to targeted therapy

.

Br J Haematol

.

2024

;

205

(

1

):

127

-

137

.

64.

Bielamowicz

K

,

Dimitrion

P

,

Abla

O

, et al;

North American Consortium for Histiocytosis

.

Langerhans cell histiocytosis: NACHO update on progress, chaos, and opportunity on the path to rational cures

.

Cancer

.

2024

;

130

(

14

):

2416

-

2439

.

65.

Bouffet

E

,

Hansford

JR

,

Garrè

ML

, et al.

Dabrafenib plus trametinib in pediatric glioma with BRAF V600 Mutations

.

N Engl J Med

.

2023

;

389

(

12

):

1108

-

1120

.

66.

Bouffet

E

,

Geoerger

B

,

Moertel

C

, et al.

Efficacy and safety of trametinib monotherapy or in combination with dabrafenib in pediatric BRAF V600-mutant low-grade glioma

.

J Clin Oncol

.

2023

;

41

(

3

):

664

-

674

.

67.

Tardieu

M

,

Néron

A

,

Duvert-Lehembre

S

, et al.

Cutaneous adverse events in children treated with vemurafenib for refractory BRAFV600E mutated Langerhans cell histiocytosis

.

Pediatr Blood Cancer

.

2021

;

68

(

9

):

e29140

.

68.

McCannel

TA

,

Chmielowski

B

,

Finn

RS

, et al.

Bilateral subfoveal neurosensory retinal detachment associated with MEK inhibitor use for metastatic cancer

.

JAMA Ophthalmol

.

2014

;

132

(

8

):

1005

-

1009

.

69.

Jeng-Miller

KW

,

Miller

MA

,

Heier

JS.

Ocular effects of MEK inhibitor therapy: literature review, clinical presentation, and best practices for mitigation

.

Oncologist

.

2024

;

29

(

5

):

e616

-

e621

.

70.

Mincu

RI

,

Mahabadi

AA

,

Michel

L

, et al.

Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta- analysis

.

JAMA Netw Open

.

2019

;

2

(

8

):

e198890

.

71.

Banks

M

,

Crowell

K

,

Proctor

A

,

Jensen

BC.

Cardiovascular Effects of the MEK inhibitor, trametinib: a case report, literature review, and consideration of mechanism

.

Cardiovasc Toxicol

.

2017

;

17

(

4

):

487

-

493

.

72.

Sconocchia

T

,

Foßelteder

J

,

Sconocchia

G

,

Reinisch

A

.

Langerhans cell histiocytosis: current advances in molecular pathogenesis

.

Front Immunol

.

2023

;

14

:

1275085

.

73.

Long

GV

,

Flaherty

KT

,

Stroyakovskiy

D

, et al.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

.

Ann Oncol

.

2017

;

28

(

7

):

1631

-

1639

.

74.

Kilburn

LB

,

Khuong-Quang

D-A

,

Hansford

J-R

, et al.

The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial

.

Nat Med

.

2024

;

30

(

1

):

207

-

217

.

75.

Lei

J

,

Wang

W

,

Lin

D

, et al.

Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study

.

J Cancer Res Clin Oncol

.

2024

;

150

(

1

):

12

.

76.

Heisig

A

,

Sörensen

J

,

Zimmermann

S-Y

, et al.

Vemurafenib in Langerhans cell histiocytosis: report of a pediatric patient and review of the literature

.

Oncotarget

.

2018

;

9

(

31

):

22236

-

22240

.

77.

Hazim

AZ

,

Ruan

GJ

,

Ravindran

A

, et al.

Efficacy of BRAF-inhibitor therapy in BRAFV600E-mutated adult Langerhans cell histiocytosis

.

Oncologist

.

2020

;

25

(

12

):

1001

-

1004

.

78.

Abraham

A

,

Alsultan

A

,

Jeng

M

,

Rodriguez-Galindo

C

,

Campbell

PK.

Clofarabine salvage therapy for refractory high-risk Langerhans cell histiocytosis

.

Pediatr Blood Cancer

.

2013

;

60

(

6

):

E19

-

E22

.

79.

Weitzman

S

,

Braier

J

,

Donadieu

J

, et al.

2′-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). Results of the LCH-S-98 protocol of the Histiocyte Society

.

Pediatr Blood Cancer

.

2009

;

53

(

7

):

1271

-

1276

.

80.

Donadieu

J

,

Bernard

F

,

van Noesel

M

, et al;

Salvage Group of the Histiocyte Society

.

Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study

.

Blood

.

2015

;

126

(

12

):

1415

-

1423

.

81.

Wang

W

,

Ge

J

,

Ma

H

, et al.

Cladribine and cytarabine in children refractory high risk multisystem Langerhans cell histiocytosis

.

Heliyon

.

2023

;

9

(

9

):

e19277

.

82.

Veys

PA

,

Nanduri

V

,

Baker

KS

, et al.

Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning

.

Br J Haematol

.

2015

;

169

(

5

):

711

-

718

.

83.

Meng

G

,

Feng

S

,

Wang

Y

.

Advances in allogeneic hematopoietic stem cell transplantation for Langerhans cell histiocytosis in children

.

Front Immunol

.

2025

;

16

:

1345855

.

84.

Karri

V

,

Lin

H

,

Velazquez

J

, et al.

Clinical, radiological and molecular responses to combination chemotherapy with MAPK pathway inhibition in relapsed and refractory Langerhans cell histiocytosis

.

Br J Haematol

.

2024

;

204

(

5

):

1882

-

1887

.

85.

Evseev

D

,

Osipova

D

,

Kalinina

I

, et al.

Vemurafenib combined with cladribine and cytarabine results in durable remission of pediatric BRAF V600E-positive LCH

.

Blood Adv

.

2023

;

7

(

18

):

5246

-

5257

.

86.

Cui

L

,

Zhang

L

,

Ma

H-H

, et al.

Circulating cell-free BRAF V600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis

.

Haematologica

.

2020

;

105

(

9

):

e444

-

e447

.

87.

Berres

M-L

,

Merad

M

,

Allen

C-E

.

Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X?

Br J Haematol

.

2015

;

169

(

1

):

3

-

13

.

88.

Minkov

M

,

Steiner

M

,

Pötschger

U

, et al;

International LCH Study Group

.

Reactivations in multisystem Langerhans cell histiocytosis: data of the international LCH registry

.

J Pediatr

.

2008

;

153

(

5

):

700

-

705

,

705.e1-25

,

705e1

.

89.

Lau

LM

,

Stuurman

K

,

Weitzman

S.

Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors

.

Pediatr Blood Cancer

.

2008

;

50

(

3

):

607

-

612

.

90.

Haupt

R

,

Nanduri

V

,

Calevo

MG

, et al.

Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group

.

Pediatr Blood Cancer

.

2004

;

42

(

5

):

438

-

444

.

91.

Sveijer

M

,

Gavhed

D

,

Hertzberg

H

,

Zander

E

,

Henter

J-I

,

von Bahr Greenwood

T

.

Quality of life, fatigue, depression, attention deficits, and pain after childhood Langerhans cell histiocytosis

.

Blood Neoplasia

.

2025

;

2

(

3

):

100098

.

92.

Sláma

T

,

Mader

L

,

Žarković

M

, et al.

Chronic health conditions after childhood Langerhans cell histiocytosis: results from the Swiss Childhood Cancer Survivor Study

.

J Cancer Surviv

.

2025

;

19

(

4

):

1212

-

1221

.

93.

Gadner

H

,

Grois

N

,

Arico

M

, et al;

Histiocyte Society

.

A randomized trial of treatment for multisystem Langerhans' cell histiocytosis

.

J Pediatr

.

2001

;

138

(

5

):

728

-

734

.

94.

Destombes

P.

Adenitis with lipid excess, in children or young adults, seen in the Antilles and in Mali. (4 cases) [in French]

.

Bull Soc Pathol Exot Filiales

.

1965

;

58

(

6

):

1169

-

1175

.

95.

Rosai

J

,

Dorfman

RF.

Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity

.

Arch Pathol

.

1969

;

87

(

1

):

63

-

70

.

96.

Foucar

E

,

Rosai

J

,

Dorfman

R.

Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity

.

Semin Diagn Pathol

.

1990

;

7

(

1

):

19

-

73

.

97.

Mahzoni

P

,

Zavareh

MH

,

Bagheri

M

,

Hani

N

,

Moqtader

B.

Intracranial ROSAI-DORFMAN Disease

.

J Res Med Sci

.

2012

;

17

(

3

):

304

-

307

.

98.

Campo

E

,

Jaffe

ES

,

Cook

JR

, et al.

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

.

Blood

.

2022

;

140

(

11

):

1229

-

1253

.

99.

Emile

J-F

,

Abla

O

,

Fraitag

S

, et al;

Histiocyte Society

.

Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages

.

Blood

.

2016

;

127

(

22

):

2672

-

2681

.

100.

Baraban

E

,

Sadigh

S

,

Rosenbaum

J

, et al.

Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease

.

Br J Haematol

.

2019

;

186

(

6

):

837

-

844

.

101.

Ravindran

A

,

Goyal

G

,

Go

RS

,

Rech

KL

;

Mayo Clinic Histiocytosis Working Group

.

Rosai-Dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2

.

Am J Surg Pathol

.

2021

;

45

(

1

):

35

-

44

.

102.

Ravindran

A

,

Rech

KL.

How I diagnose Rosai-Dorfman disease

.

Am J Clin Pathol

.

2023

;

160

(

1

):

1

-

10

.

103.

Elbaz Younes

I

,

Sokol

L

,

Zhang

L

.

Rosai-Dorfman disease between proliferation and neoplasia

.

Cancers (Basel)

.

2022

;

14

(

21

):

5271

.

104.

Goyal

G

,

Young

JR

,

Koster

MJ

, et al;

Mayo Clinic Histiocytosis Working Group

.

The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease

.

Mayo Clin Proc

.

2019

;

94

(

10

):

2054

-

2071

.

105.

Averitt

AW

,

Heym

K

,

Akers

L

,

Castro-Silva

F

,

Ray

A.

Sinus histiocytosis with massive lymphadenopathy (Rosai Dorfman disease): diagnostic and treatment modalities for this rare entity revisited

.

J Pediatr Hematol Oncol

.

2018

;

40

(

4

):

e198

-

e202

.

106.

Mahajan

S

,

Nakajima

R

,

Yabe

M

, et al.

Rosai-Dorfman disease-utility of 18F-FDG PET/CT for initial evaluation and follow-up

.

Clin Nucl Med

.

2020

;

45

(

6

):

e260

-

e266

.

107.

Leung

E

,

Pryma

C

,

Murphy

S

, et al.

Rosai-Dorfman-Destombes disease in adults: a single center experience

.

Ann Hematol

.

2024

;

103

(

11

):

4467

-

4476

.

108.

Simko

SJ

,

Tran

HD

,

Jones

J

, et al.

Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease

.

Pediatr Blood Cancer

.

2014

;

61

(

3

):

479

-

487

.

109.

Pulsoni

A

,

Anghel

G

,

Falcucci

P

, et al.

Treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): report of a case and literature review

.

Am J Hematol

.

2002

;

69

(

1

):

67

-

71

.

110.

Diamond

EL

,

Durham

BH

,

Ulaner

GA

, et al.

Efficacy of MEK inhibition in patients with histiocytic neoplasms

.

Nature

.

2019

;

567

(

7749

):

521

-

524

.

111.

Abeykoon

JP

,

Rech

KL

,

Young

JR

, et al;

Mayo Clinic–University of Alabama at Birmingham Histiocytosis Working Group

.

Outcomes after treatment with cobimetinib in patients with Rosai-Dorfman disease based on KRAS and MEK alteration status

.

JAMA Oncol

.

2022

;

8

(

12

):

1816

-

1820

.

112.

Aaroe

A

,

Kurzrock

R

,

Goyal

G

, et al.

Successful treatment of non-Langerhans cell histiocytosis with the MEK inhibitor trametinib: a multicenter analysis

.

Blood Adv

.

2023

;

7

(

15

):

3984

-

3992

.

113.

Cuerden

C

,

Alsalem

M

,

Sproson

E

, et al.

MEK inhibition with trametinib for the treatment of MAP2K1-mutated Rosai-Dorfman-destombes disease arising from the nasopharynx in a paediatric patient

.

Pediatr Blood Cancer

.

2025

;

72

(

5

):

e31595

.